Get a fresh start.
Add this topic to your myFT Digest for news straight to your inbox
Shingles and meningitis treatments help offset blow from generic version of key drug
Bold decisions being taken by chief executive Emma Walmsley should pay off
Dovato shown to be as effective as Gilead’s traditional combination treatment
Staff encouraged to take more risks in pursuit of blockbuster medicines
UK drugmaker has been under pressure to produce new money-spinning medicines
HSBC deputy chair and former Astra finance chief to oversee break-up of UK pharma group
Drugmaker will fund 20 scientists in rare partnership with University of CaliforniaS
Drugmaker to link bonuses to number of prescriptions written for its medicines
Group beats expectations but warns generic alternative will hit best-selling asthma drug
GSK drug to be piloted as part of landmark project across Africa
City veteran plans to keep on sailing after transatlantic crossing
Clinical trials show reduced regimen still effective at controlling virus
ViiV Healthcare regimen hoped to offer less toxic alternative to daily tablets
Lengthy inventory of longstanding investigations prompts tough decisions
Two of the anti-fraud agency’s biggest and longest-running cases are brought to a close
UK drugmaker warns 2019 earnings likely to be hit by generic rival to Advair asthma drug
UK group to pay up to €3.7bn to co-develop novel class of immunology
Some find group’s prospects not worth waiting for, but others see recipe for success
Philip Hampton praised as ‘change agent’ despite concerns over share price
The CEO has lost no time in ruthlessly reshaping the health and pharmaceuticals group
Chief Emma Walmsley’s JV plan will make investors’ ears perk up
Cash influx intended to bolster search for blockbuster drugs and dealmaking
Drugmaker plans to split in two after spinning off consumer product unit
Deal leaves UK pharma group in the driving seat, without a cash acquisition cost
